Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ZK219477 infusion duration in recurrent platinum-resistant ovarian cancer
2005-000635-15Phase 2Completed
- Sponsor
- Schering AG
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sagopilone in ovarian cancer (2 arms), sponsored by Schering AG. Primary endpoint: Primary efficacy endpoint in patients with measurable disease. Started Jun 2005; status: completed.
02
Drugs
sagopilone
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2005-000635-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000635-15.